KR30031
- CAS NO.：205535-74-6
- Empirical Formula: C26H34N2O4
- Molecular Weight: 438.56
- Update Date: 2026-05-11 19:39:08
What is KR30031?
Description
KR30031 is a novel P-glycoprotein inhibitor with potential anticancer activity. KR30031 is a verapamil analog with fewer cardiovascular effects. The ability of KR-30031 to reduce this efflux transport is equal to that of verapamil, a well-known P-glycoprotein inhibitor. The bioavailability of paclitaxel could be enhanced by coadministration of a P-glycoprotein inhibitor, KR-30031.
Properties of KR30031
| Boiling point: | 584.9±50.0 °C(Predicted) |
| Density | 1.14±0.1 g/cm3(Predicted) |
| pka | 9.24±0.50(Predicted) |
Safety information for KR30031
Computed Descriptors for KR30031
New Products
3-AMINO-3-(2-CHLORO-PHENYL)-PROPIONIC ACID 4-Fluorophenylglycine 1-Boc-3-(cyanomethyl)azetidine Dimedone 1-N-Boc-3-(aminoethyl)azetidine N-BOC-piperidine-4-carboxylic acid 4,6-Dichlororesorcinol 5-Amino-2-Bromo-3-Chloropyridine 2-Picolinic acid N-oxide 4-Butyl Resorcinol 2-Bromo-5-Chloropyridine 5-Bromo-2-Hydroxy-3-Nitro Pyridine 2-Amino-4-phenyl-thiazole N-(4-Bromophenyl)-2-chloroacetamide TRIFLOURO ACETICACID-D METHANE SULFONIC ACID-D4 PHOSPORIC ACID-D3 85 W% IN D2O DEUTERIUM OXIDE FOR NMR BENZENE-D6 TOLUENE-D3You may like
-
IODOETHANE-D5 6485-58-1 99%View Details
6485-58-1 -
32008-59-6 PARAFORMALDEHYDE-D2 98%View Details
32008-59-6 -
CHLORO BENZENE-D5 3114-55-4 99%View Details
3114-55-4 -
PHENYL ACETYLENE-D 3240-11-07 99%View Details
3240-11-07 -
918-20-7 TERT-BUTYL CHLORIDE-D9 98%View Details
918-20-7 -
84358-13-4 N-BOC-piperidine-4-carboxylic acid 98+View Details
84358-13-4 -
84358-13-4 N-BOC-piperidine-4-carboxylic acid 98+View Details
84358-13-4 -
84358-13-4 N-BOC-piperidine-4-carboxylic acid 98+View Details
84358-13-4
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.